Immunitybio Inc
NASDAQ:IBRX
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
Immunitybio Inc
NASDAQ:IBRX
|
4.4B USD | -15.6 | ||
US |
Abbvie Inc
NYSE:ABBV
|
277.3B USD | 13.1 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 18.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118B USD | 24.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.5B USD | 22.8 | ||
AU |
CSL Ltd
ASX:CSL
|
135.6B AUD | 22 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.8B USD | 8.6 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
63.8B USD | -12.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -61.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 13.9 | ||
KR |
Celltrion Inc
KRX:068270
|
37.4T KRW | 48 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.